.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BD13_MetforminAndAlogliptin.MetforminAndAlogliptin .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BD13_MetforminAndAlogliptin.MetforminAndAlogliptin| name: | MetforminAndAlogliptin |
| ATC code: | A10BD13 | route: | oral |
| n-compartments | 1 |
Metformin and alogliptin is a fixed-dose combination of two antihyperglycemic agents used in the treatment of type 2 diabetes mellitus. Metformin is a biguanide that reduces hepatic glucose production and improves insulin sensitivity, while alogliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin levels to stimulate insulin secretion and decrease glucagon levels. This combination is approved for use in adults with type 2 diabetes mellitus when diet and exercise do not provide adequate glycemic control.
Pharmacokinetic parameters estimated for usual adult population under typical dosing after oral administration; no published model specifically for the metformin and alogliptin combination, so parameters are based on combination of published values for individual components.